Page 98 - Read Online

Page 218 Cendrós et al. J Transl Genet Genom 2020;4:210-20 I http://dx.doi.org/10.20517/jtgg.2020.21

Conducted pharmacokinetic studies: Brunet M, Torra M
Performed analysis of results: Cendrós M, Arranz MJ, Catalán R
All authors contributed to the interpretation and discussion of results.

Availability of data and materials
Not applicable.

Financial support and sponsorship
This study was financed by Institute Carlos III (FIS PI11/02006 and FIS PI16/01029) and grant PT13/001,
ISCIII-SGEFI/FEDER

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
The research was performed in accordance with the Declaration of Helsinki and all participants gave
written informed consent. AEMPS code: RCC-ANT-2013-01

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, et al. Side effect burden of antipsychotic drugs in real life-Impact of gender and
polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry 2018;82:263-71.
2. McCutcheon R, Beck K, D’Ambrosio E, Donocik J, Gobjila C, et al. Antipsychotic plasma levels in the assessment of poor treatment
response in schizophrenia. Acta Psychiatr Scand 2018;137:39-46.
3. Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone
and aripiprazole: a retrospective, cohort study. Lancet Psychiatry 2019;6:418-26.
4. Ruan CJ, Zang YN, Wang CY, Cheng YH, Sun C, et al. Clozapine metabolism in east Asians and caucasians: a pilot exploration of the
prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol 2019;39:135-44.
5. Kurylev AA, Brodyansky VM, Andreev BV, Kibitov AO, Limankin OV, et al. The combined effect of CYP2D6 and DRD2 Taq1A
polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study).
Psychiatr Danub 2018;30:157-63.
6. Mas S, Gassò P, Alvarez S, Parellada E, Bernardo M, et al. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to
CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2012;12:255-9.
7. Kirchheiner J, Gründemann D, Schömig E. Contribution of allelic variations in transporters to the phenotype of drug response. J
Psychopharmacol 2006;20:27-32.
8. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:423-9.
9. Bruckmueller H, Martin P, Kähler M, Haenisch S, Ostrowski M, et al. Clinically relevant multidrug transporters are regulated by
microRNAs along the human intestine. Mol Pharm 2017;14:2245-53.
10. van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum
concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol 2015;35:228-36.
11. Filipce A, Naumovska Z, Nestorovska AK, Sterjev Z, Brezovska K, et al. Evaluation of correlation between the pharmacogenetic profiles
of risperidone treated psychiatry patients with plasma and urine concentration of risperidone and its active moiety 9-OH rsperidone
determined with optimized bioanalytical LC method. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2018;39:97-106.
12. Bakken GV, Molden E, Hermann M. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of
quetiapine and N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2015;37:256-61.
13. Suzuki T, Mihara K, Nakamura A, Kagawa S, Nagai G, et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the
steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Ther Drug Monit 2014;36:651-5.
14. González-Vacarezza N, Dorado P, Peñas-Lledó EM, Fariñas H, Estévez-Carrizo FE, et al. MDR-1 genotypes and quetiapine